Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.53 |
| ▸ | AR | P10275 | 4/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17471460 | 0.81 | PGR (0.71) | PGRNR3C2ARNR3C1 | |
| SCHEMBL4811827 | 0.79 | PGR (0.65) | PGRNR3C2AR | |
| SCHEMBL2885095 | 0.77 | PGR (0.63) | PGRAR | |
| SCHEMBL3983569 | 0.76 | PGR (1.00) | PGRNR3C2ARNR3C1 | |
| Hydrochloric Acid SCHEMBL2880085 | 0.76 | PGR (0.62) | PGRAR | |
| SCHEMBL3985057 | 0.76 | PGR (1.00) | PGRNR3C2ARNR3C1 | |
| SCHEMBL5505137 | 0.75 | PGR (0.91) | PGRNR3C2ARNR3C1 | |
| SCHEMBL4809621 | 0.74 | PGR (1.00) | PGRNR3C2ARNR3C1 | |
| SCHEMBL4420552 | 0.74 | PGR (1.00) | PGRAR | |
| SCHEMBL5508205 | 0.73 | PGR (1.00) | PGRNR3C2ARNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1980660-A | Contraceptive regimens and kits for progesterone receptor antagonists | WYETH CORP (US) | 2007-06-13 | — | — | CN | claimed |
| EP-1778222-A1 | PROGESTERONE RECEPTOR MODULATORS COMPRISING PYRROLE-OXINDOLE DERIVATIVES AND USES THEREOF | Wyeth (US) | 2007-05-02 | — | — | EP | claimed |
| EP-1773323-A1 | PROGESTERONE RECEPTOR ANTAGONIST CONTRACEPTIVE REGIMENS AND KITS | Wyeth (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006023107-A1 | PROGESTERONE RECEPTOR MODULATORS COMPRISING PYRROLE-OXINDOLE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-03-02 | — | — | WO | claimed |
| WO-2006017075-A1 | PROGESTERONE RECEPTOR ANTAGONIST CONTRACEPTIVE REGIMENS AND KITS | WYETH (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060030615-A1 | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | WYETH (US) | 2006-02-09 | — | — | US | claimed |
| US-20060009509-A1 | Progesterone receptor antagonists, contraceptive regimens, and kits | WYETH (US) | 2006-01-12 | — | — | US | claimed |
| EP-1778222-A1 | PROGESTERONE RECEPTOR MODULATORS COMPRISING PYRROLE-OXINDOLE DERIVATIVES AND USES THEREOF | Wyeth (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006023107-A1 | PROGESTERONE RECEPTOR MODULATORS COMPRISING PYRROLE-OXINDOLE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060030615-A1 | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030615-A1 | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | PGR, PGRMC2, PGRMC1 | PGR 1/4885NR3C2 18/4885AR 122/4885 |
| US-20060009509-A1 | Progesterone receptor antagonists, contraceptive regimens, and kits | GNRHR, PGRMC2, PGR | PGR 3/4885NR3C2 42/4885AR 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.